Erectile Dysfunction Drugs Market Size is valued at USD 2.58 billion in 2023 and is predicted to reach USD 4.60 billion by the year 2031 at a 7.7% CAGR during the forecast period for 2024-2031.
Erectile dysfunction refers to the condition where an individual is unable to gain or maintain an erection for a sufficient duration to engage in sexual activity. Sedentary lifestyle-related chronic disorders, including obesity, heart disease, diabetes, and hypertension, are major contributors to erectile dysfunction. Improvements in pharmacological research and development for erectile dysfunction treatments, a growing number of men suffering from the illness, and an aging population are all factors propelling the erectile dysfunction drugs market. An increase in R&D, a dramatic increase in the number of men with erectile dysfunction, and a general upsurge in the prevalence of chronic diseases, which include obesity, hypertension, and diabetes, are all factors propelling the industry ahead. In addition, the erectile dysfunction medications market is experiencing strong growth and demand, driven by several major factors, such as the increasing prevalence of lifestyle disorders and the widespread adoption of sedentary lifestyles.
However, the market expansion is impeded by stringent regulatory standards regarding the safety and health of the erectile dysfunction drugs market. Additionally, the prevalence of numerous side effects linked to this medication poses a risk to its growth. Furthermore, low patient adherence and the presence of cheaper counterfeit drugs are anticipated to decelerate the market for erectile dysfunction drugs. Global healthcare systems are under strain due to the COVID-19 epidemic. During a pandemic, the number of sterilization treatments performed by biotechnology and pharmaceutical businesses increases due to increased research and development activities and medicine manufacture. Because of this, the chemicals market is expected to experience expansion.
Competitive Landscape
Some of the erectile dysfunction drugs market key players are:
- Cipla Limited
- Eli Lilly and Company
- Sanofi S.A.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Vivus, Inc.
- GlaxoSmithKline PLC
- Adamed Sp. z o.o.
- Bayer AG
- Reddys Laboratories Ltd.
- Endo International PLC
- Futura Medical PLC
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
- K. Chemicals Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
Market Segmentation:
The erectile dysfunction drugs market is segmented based on drug, mode of administration, and distribution channel. The drug segment is categorized into avanafil (Stendra), muse suppository (Alprostadil), sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra, Staxyn). The mode of administration segment includes injections, oral, and topical. The distribution channel segment includes hospital pharmacies, online pharmacies, and retail pharmacies.
Based On The Distribution Channel, The Retail Pharmacists' Segment Is Accounted As A Major Contributor To The Erectile Dysfunction Drugs Market
Retail pharmacists in the erectile dysfunction drugs market are expected to witness a significant global market share in 2023. They dispense pharmaceuticals and medical supplies to both the general public and other healthcare professionals, as well as a wide variety of personal care items, art supplies, photography equipment, and pet supplies.
Oral Industry Segment To Witness Growth At A Rapid Rate
The oral sector predominantly utilizes erectile dysfunction pharmaceuticals due to their exceptional efficacy and safety profile, making them the preferred choice, particularly in different countries such as the US, Germany, the UK, China, and India.
The North American Market For Erectile Dysfunction Drugs Occupies A Substantial Portion Of The Region's Total Revenue.
In the near future, the North American market for erectile dysfunction medications is projected to have the most significant market share in revenue. The plethora of research and development efforts focused on creating new pharmacological compounds, the growing need for medications to address erectile dysfunction, and the robust healthcare infrastructure in the region are the main factors contributing to this phenomenon. Furthermore, the Asia Pacific region is expected to experience noteworthy growth in the global market for erectile dysfunction pharmaceuticals. This may be attributed to the increasing population of elderly patients, the thriving generic pharmaceutical industry, and the prevalence of infections related to erectile dysfunction in this geographical area.
Global Erectile Dysfunction Drugs Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.58 Bn |
|
Revenue Forecast In 2031 |
USD 4.60 Bn |
|
Growth Rate CAGR |
CAGR of 7.7 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug, Mode Of Administration, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Adamed Sp. z o.o., Bayer AG, Cipla Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, Endo International PLC, Futura Medical PLC, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novartis International AG, Pfizer Inc., S.K. Chemicals Co. Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vivus, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
